Neurotransmitter, neuropeptide and gut peptide profile in PCOS-pathways contributing to the pathophysiology, food intake and psychiatric manifestations of PCOS.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and observational literature without systematic methodology
PubMed 32362321 · doi:10.1016/bs.acc.2019.11.004
What was done
This is a narrative review synthesizing literature on the involvement of central neurotransmitters (such as catecholamines, serotonin, and endogenous opioids), neuropeptides, and gut-brain axis peptides in the pathophysiology, metabolic disturbances, appetite regulation, and psychiatric symptoms associated with polycystic ovary syndrome (PCOS).
What was found
The abstract provides no numerical data, effect sizes, or study counts. It describes qualitative evidence that altered catecholamine metabolism and brain serotonin or opioid activity correlate with abnormal gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) release, and that dysregulated central and gut peptide signaling is linked to obesity, insulin resistance, abnormal appetite, anxiety, and depression in women with PCOS.
Why it matters
The review outlines how neuroendocrine and gut-brain axis disruptions may unite the reproductive, metabolic, and psychiatric features of PCOS, highlighting potential targets for future pharmacological interventions.
Limits
As a narrative review, it presents no primary experimental data, sample size details, or systematic review protocol. The mechanistic pathways described do not establish definitive causality between specific peptide alterations and clinical PCOS phenotypes.
Cited by
- context Elevated androgens in PCOS disrupt brain dopamine and serotonin signaling.